Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin

Chee Hoo Yip, Orr Yarkoni, James Ajioka, Kiew Lian Wan, Sheila Nathan

Research output: Contribution to journalArticle

Abstract

Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially compliant surrogate host.

Original languageEnglish
JournalApplied Microbiology and Biotechnology
DOIs
Publication statusAccepted/In press - 1 Jan 2019

Fingerprint

Prodigiosin
Pharmaceutical Preparations
Serratia marcescens
Synthetic Biology
Bioengineering
Textiles
Drug Delivery Systems
Immunosuppressive Agents
Coloring Agents
Bacteria

Keywords

  • Beneficial secondary metabolite
  • Bifurcated pathway
  • Gene cluster
  • High-level synthesis
  • Prodigiosin

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin. / Yip, Chee Hoo; Yarkoni, Orr; Ajioka, James; Wan, Kiew Lian; Nathan, Sheila.

In: Applied Microbiology and Biotechnology, 01.01.2019.

Research output: Contribution to journalArticle

@article{6fc1c10f0d0345018392b69b1f2de21e,
title = "Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin",
abstract = "Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially compliant surrogate host.",
keywords = "Beneficial secondary metabolite, Bifurcated pathway, Gene cluster, High-level synthesis, Prodigiosin",
author = "Yip, {Chee Hoo} and Orr Yarkoni and James Ajioka and Wan, {Kiew Lian} and Sheila Nathan",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00253-018-09611-z",
language = "English",
journal = "Applied Microbiology and Biotechnology",
issn = "0175-7598",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin

AU - Yip, Chee Hoo

AU - Yarkoni, Orr

AU - Ajioka, James

AU - Wan, Kiew Lian

AU - Nathan, Sheila

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially compliant surrogate host.

AB - Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially compliant surrogate host.

KW - Beneficial secondary metabolite

KW - Bifurcated pathway

KW - Gene cluster

KW - High-level synthesis

KW - Prodigiosin

UR - http://www.scopus.com/inward/record.url?scp=85060019920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060019920&partnerID=8YFLogxK

U2 - 10.1007/s00253-018-09611-z

DO - 10.1007/s00253-018-09611-z

M3 - Article

JO - Applied Microbiology and Biotechnology

JF - Applied Microbiology and Biotechnology

SN - 0175-7598

ER -